DURECT Provides Update on CHRONOGESIC(R) Research Program

CUPERTINO, Calif., April 7, 2008 DURECTCorporation (Nasdaq: DRRX) announced today that Endo Pharmaceuticals hasstated that it intends to return the rights to CHRONOGESIC(R) licensed fromDURECT Corporation for the U.S. and Canada. CHRONOGESIC is a productcandidate consisting of a sufentanil containing implantable device intendedfor the treatment of moderate-to-severe chronic pain. As a result, theDevelopment, Commercialization and Supply License Agreement between Endo andDURECT entered into in November 2002 will terminate. This return ofCHRONOGESIC rights has no effect on DURECT and Endo's collaboration withrespect to the sufentanil transdermal patch (TRANSDUR(TM)-Sufentanil) licensedby Endo from DURECT for the U.S. and Canada.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company focusedon the development of pharmaceutical systems based on its proprietary drugdelivery platform technologies focused on treating chronic and episodicdiseases and conditions. The Company currently has multiple late-stagepharmaceutical products in development initially focused on significant unmetmedical needs in pain management, with a number of research programs underwayin a variety of other therapeutic areas. For more information, please visithttp://www.durect.com.

NOTE: CHRONOGESIC(R) and TRANSDUR(TM) are trademarks of DURECTCorporation. Other referenced trademarks belong to their respective owners.TRANSDUR-Sufentanil is a drug candidate under development and has not beensubmitted or approved for commercialization by the US Food and DrugAdministration or other health authorities.

DURECT Forward-Looking Statement

The statement in this press release regarding DURECT's emergence as aspecialty pharmaceutical company and DURECT's product candidates are forward-looking statements involving risks and uncertainties that can cause actualresults to differ materially from those in such forward-looking statements.Potential risks and uncertainties include, but are not limited to, DURECT's(and that of its third party collaborators where applicable) abilities toobtain approvals from regulatory agencies with respect to its developmentactivities and product candidates, design, enroll, conduct and completeclinical trials, complete the design, development, and manufacturing processdevelopment of the product candidates, consummate collaborative agreementsrelating to our product candidates and technologies, manufacture andcommercialize the product candidates, obtain marketplace acceptance of theproduct candidates and manage and obtain capital to fund its growth,operations and expenses. Further information regarding these and other risksis included in DURECT's Form 10-K dated March 13, 2008 under the heading "RiskFactors."

SOURCE DURECT Corporation

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...